BR112021020924A2 - Uso de um anticorpo anti-cd19 para tratar doença autoimune - Google Patents

Uso de um anticorpo anti-cd19 para tratar doença autoimune

Info

Publication number
BR112021020924A2
BR112021020924A2 BR112021020924A BR112021020924A BR112021020924A2 BR 112021020924 A2 BR112021020924 A2 BR 112021020924A2 BR 112021020924 A BR112021020924 A BR 112021020924A BR 112021020924 A BR112021020924 A BR 112021020924A BR 112021020924 A2 BR112021020924 A2 BR 112021020924A2
Authority
BR
Brazil
Prior art keywords
antibody
autoimmune disease
treat autoimmune
treat
vib551
Prior art date
Application number
BR112021020924A
Other languages
English (en)
Inventor
Eliezer Katz
Jorn Drappa
Kathleen Mckeever
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of BR112021020924A2 publication Critical patent/BR112021020924A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

uso de um anticorpo anti-cd19 para tratar doença autoimune. a presente invenção refere-se a métodos para usar um anti-corpo anti-cd19 para tratar doença autoimune. em particular do uso de vib551, um anticorpo monoclonal kappa igg1 afucosilado, otimizado para afinidade, humanizado para tratar distúrbio do espectro da neuromielite óptica.
BR112021020924A 2019-04-24 2020-04-23 Uso de um anticorpo anti-cd19 para tratar doença autoimune BR112021020924A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US201962858495P 2019-06-07 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
BR112021020924A2 true BR112021020924A2 (pt) 2022-04-19

Family

ID=72940915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020924A BR112021020924A2 (pt) 2019-04-24 2020-04-23 Uso de um anticorpo anti-cd19 para tratar doença autoimune

Country Status (12)

Country Link
US (1) US20220204617A1 (pt)
EP (1) EP3959241A4 (pt)
JP (1) JP2022529743A (pt)
KR (1) KR20220004113A (pt)
CN (1) CN113939532A (pt)
AU (1) AU2020263418A1 (pt)
BR (1) BR112021020924A2 (pt)
CA (1) CA3136487A1 (pt)
IL (1) IL287385A (pt)
MX (1) MX2021012870A (pt)
SG (1) SG11202111429UA (pt)
WO (1) WO2020219743A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
WO2022236047A1 (en) * 2021-05-07 2022-11-10 Viela Bio, Inc. Use of an anti-cd19 antibody to treat myasthenia gravis
WO2024025602A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Inebilizumab and methods of using the same for sustained b-cell depletion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002414A (es) * 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
CN104640560A (zh) * 2012-03-12 2015-05-20 米迪缪尼有限公司 用抗-cd19抗体治疗多发性硬化症
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Also Published As

Publication number Publication date
WO2020219743A3 (en) 2020-12-10
US20220204617A1 (en) 2022-06-30
SG11202111429UA (en) 2021-11-29
IL287385A (en) 2021-12-01
CA3136487A1 (en) 2020-10-29
MX2021012870A (es) 2022-01-18
EP3959241A4 (en) 2023-01-25
WO2020219743A2 (en) 2020-10-29
AU2020263418A1 (en) 2021-11-11
JP2022529743A (ja) 2022-06-23
KR20220004113A (ko) 2022-01-11
EP3959241A2 (en) 2022-03-02
CN113939532A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
BR112021020924A2 (pt) Uso de um anticorpo anti-cd19 para tratar doença autoimune
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
CL2022002335A1 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
EA200970556A1 (ru) Моноклональные антитела против angptl3
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
UY38244A (es) AGENTES ENLAZANTES DE PSMA y SUS USOS
CL2022000127A1 (es) Anticuerpos que se fijan a gprc5d
AR114112A1 (es) Anticuerpos de glipicano 3 y conjugados de los mismos
DOP2014000052A (es) Anticuerpo anti-alfabeta tcr
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
CO2022013898A2 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
EA202192130A1 (ru) Специфичные к ltbp-комплексу ингибиторы tgf и их применение
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
EA202092420A1 (ru) Антитело против pd-l1 и его применение
CO2021000386A2 (es) Anticuerpos humanizados contra psma
EP3825334A4 (en) HUMANIZED MONOCLONAL ANTIBODY ANTI-HER3
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
CO2022010204A2 (es) Anticuerpos contra la integrina alfa 11 beta 1
AR120093A1 (es) Anticuerpos anti-ceacam y usos de los mismos